{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056871","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.409269+00:00","generated_at":"2026-06-02T06:10:22.270465+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kezar Life Sciences Q1 net loss $21.7M; cash $179.8M; clinical trials on track","bullets":["Cash, cash equivalents and marketable securities totaled $179.8M as of March 31, 2024, down from $201.4M at Dec 31, 2023.","Net loss $21.7M ($0.30 per share) vs $22.2M ($0.31) in Q1 2023; R&D expenses $17.2M, G&A $6.5M.","PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.","PORTOLA Phase 2a for autoimmune hepatitis enrolling; topline data expected mid-2025.","KZR-261 dose expansion in melanoma enrolling; initial study data expected by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056871","json":"https://secwatch.observer/filing/0000950170-24-056871.json","markdown":"https://secwatch.observer/filing/0000950170-24-056871.md","text":"https://secwatch.observer/filing/0000950170-24-056871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/0000950170-24-056871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/kzr-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:10:22.270465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8460e4ebdb89a30ef7705f93833fb9da065452bf","claim":"Kezar Life Sciences, Inc. reported first quarter ended March 31, 2024 results: net income $21.7 million, EPS $0.30 per basic and diluted common share.","evidence_excerpt":"Net loss for the first quarter of 2024 was $21.7 million, or $0.30 per basic and diluted common share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/0000950170-24-056871-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$21.7 million"},{"label":"EPS","value":"$0.30 per basic and diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}